Carolyn M. Rucci - 26 Jan 2026 Form 3 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role
SVP, Chief Legal Officer
Signature
/s/ Carolyn M. Rucci
Issuer symbol
AKBA
Transactions as of
26 Jan 2026
Net transactions value
$0
Form type
3
Filing time
03 Feb 2026, 16:32:46 UTC
Next filing
03 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rucci Carolyn M. SVP, Chief Legal Officer C/O AKEBIA THERAPEUTICS, INC, 245 FIRST ST., CAMBRIDGE /s/ Carolyn M. Rucci 03 Feb 2026 0002107264

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AKBA Common Stock 171,816 26 Jan 2026 Direct
holding AKBA Common Stock 36,800 26 Jan 2026 Direct F1
holding AKBA Common Stock 99,534 26 Jan 2026 Direct F2
holding AKBA Common Stock 160,000 26 Jan 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AKBA Employee Stock Option (right to buy) 26 Jan 2026 Common Stock 61,000 $2.88 Direct F3
holding AKBA Employee Stock Option (right to buy) 26 Jan 2026 Common Stock 27,900 $2.16 Direct F4
holding AKBA Employee Stock Option (right to buy) 26 Jan 2026 Common Stock 165,600 $0.6300 Direct F4
holding AKBA Employee Stock Option (right to buy) 26 Jan 2026 Common Stock 224,000 $1.68 Direct F5
holding AKBA Employee Stock Option (right to buy) 26 Jan 2026 Common Stock 240,000 $2.24 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. All of the restricted stock units will vest on January 31, 2026, subject to the reporting person's continued service with the Issuer on such vesting date.
F2 The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
F3 The options were granted by the Issuer as an inducement material to the reporting person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.
F4 The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.
F5 The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.